Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome
NCT ID: NCT05035030
Last Updated: 2025-12-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
70 participants
INTERVENTIONAL
2021-09-03
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The participants of this study will have ALGS a rare genetic disorder that can affect multiple organ systems of the body including the liver, heart, skeleton, eyes and kidneys. Common symptoms, which often develop during the first three months of life, include blockage of the flow of bile from the liver (cholestasis), yellowing of the skin and mucous membranes (jaundice), poor weight gain and growth and severe itching (pruritis).
The drug used for the study is odevixibat and was authorized for the treatment of cholestatic pruritus in infants with ALGS over 12 months of age by the United States Food and Drug Administration on 13 June 2023.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study will consist of 2 or 3 periods:
1. A 'Treatment period' of 72 weeks (cohort 1) or 12 weeks (cohort 2). Participants will visit the clinic every 4 to 12 weeks and will receive a dose of 120 μg/kg odevixibat daily.
2. An 'Optional extension period' where participants who wish to continue receiving odevixibat after the 'treatment period' will have the opportunity to remain on treatment with visits every 16 weeks until the drug is commercially available. The optional extension is available provided continued use is supported by the risk-benefit profile, the participant has not been previously withdrawn or discontinued from the study, and the study is not terminated by the Sponsor.
3. A 'Safety follow-up period' of 4 weeks (cohort 1) or 2 weeks (cohort 2). The Safety Follow-up Period will not occur for those who remain on treatment in the optional extension period.
Participants will need to complete an e-diary and questionnaires throughout the study (cohort 1 only). Participants will undergo blood samplings, urine collections (cohort 1 only), physical examinations, and clinical evaluations. They may continue some other medications, but the details need to be recorded.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Odevixibat (A4250)
Capsules for oral administration once daily for 72 weeks.
Odevixibat
Odevixibat is a small molecule and selective inhibitor of IBAT.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Odevixibat
Odevixibat is a small molecule and selective inhibitor of IBAT.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Completion of the 24-week Treatment Period of Study A4250-012
2. Signed informed consent and assent as appropriate. Patients who turn 18 years of age (or legal age per country) during the study will be required to re-consent to remain on the study
3. Caregivers (and age-appropriate patients) must be willing and able to use an electronic diary (eDiary) device as required by the study
4. Sexually active males and females must agree to use a reliable contraceptive method with ≤1% failure rate (such as hormonal contraception, intra-uterine device, or complete abstinence) from signed informed consent through 90 days after last dose of study drug.
Cohort 2 :
1. Infant with clinically confirmed ALGS , ≤11 months of age at Study Day 1
2. Body weight ≥2 kg at Study Day 1
3. Gestational age ≥36 weeks. For children born with gestational age between 32 and 36 weeks, a postmenstrual age of ≥36 weeks is required .
4. Signed parent/legal guardian informed consent.
Exclusion Criteria
1. Decompensated liver disease, history or presence of clinically significant ascites, variceal hemorrhage, and/or encephalopathy
2. Patients who were not compliant with study drug treatment or procedures in Study A4250-012
3. Any other conditions or abnormalities which, in the opinion of the investigator, may compromise the safety of the patient, or interfere with the patient participating in or completing the study
4. Known hypersensitivity to any components of odevixibat
Cohort 2 :
1. Patient with past medical history or ongoing presence of other types of liver disease including, but not limited to, the following:
1. Biliary atresia of any kind
2. Progressive familial intrahepatic cholestasis (PFIC)
3. Benign recurrent intrahepatic cholestasis
2. Patient with a past medical history or ongoing presence of any other disease or condition known to interfere with the absorption, distribution, metabolism (specifically bile acid metabolism), or excretion of drugs in the intestine, including but not limited to, inflammatory bowel disease
3. Patient with past medical history or ongoing chronic diarrhea requiring intravenous fluid or nutritional intervention for treatment of the diarrhea and/or its sequelae
4. Patient has a confirmed past diagnosis of infection with human immunodeficiency virus or other present and active, clinically significant chronic infection
5. Recent infection requiring hospitalization or treatment with parenteral anti-infective within 4 weeks of Study Day 1 or completion of oral anti-infective treatment within 2 weeks prior to the Screening Visit
6. Cancer diagnosis (except for basal cell carcinoma)
7. Chronic kidney disease with an impaired renal function and a glomerular filtration rate \<70 mL/min/1.73 m2
8. Patient with surgical history of disruption of the enterohepatic circulation (biliary diversion surgery) within 6 months prior to the Screening Visit
9. Patient has had a liver transplant, or a liver transplant is planned within 6 months of Study Day 1
10. Decompensated liver disease, history or presence of clinically significant ascites, variceal hemorrhage, and/or encephalopathy
11. International normalized ratio (INR) \>1.4 (the patient may be treated with Vitamin K, and if INR is ≤1.4 at resampling the patient may be enrolled)
12. Serum alanine aminotransferase (ALT) \>10 × upper limit of normal (ULN) at Screening
13. Serum ALT \>15 × ULN at any time point during the last 6 months unless an alternate etiology was confirmed for the elevation
14. Total bilirubin \>15 × ULN at Screening
15. Patient suffers from uncontrolled, recalcitrant pruritic condition other than ALGS. Examples include, but not limited to, refractory atopic dermatitis or other primary pruritic skin diseases.
16. Patient exposed to alcohol or substance abuse in utero
17. Bile acid or lipid binding resins and medications that slow gastrointestinal motility
18. Patient has had investigational exposure to a drug, biologic agent, or medical device within 30 days prior to the Screening Visit, or 5 half-lives of the study agent, whichever is longer
19. Any other conditions or abnormalities which, in the opinion of the investigator may compromise the safety of the patient, or interfere with the patient participating in or completing the study
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Albireo, an Ipsen Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ipsen Medical Director
Role: STUDY_DIRECTOR
Ipsen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rady Children's Hospital
San Diego, California, United States
UCSF
San Francisco, California, United States
University of California San Francisco (UCSF)
San Francisco, California, United States
Children's Healthcare of Atlanta
Atlanta, Georgia, United States
Riley Hospital for Children at IU Health
Indianapolis, Indiana, United States
Johns Hopkins Hospital
Baltimore, Maryland, United States
Boston Children's Hospital
Boston, Massachusetts, United States
Children's Mercy Hospital and Clinics
Kansas City, Missouri, United States
Northwell Health System
New Hyde Park, New York, United States
Hassenfeld Children's Hospital at NYU Langone
New York, New York, United States
The Childrens Hospital at Montefiore Albert Einstein School of Medicine
The Bronx, New York, United States
Atrium Health Carolinas Medical
Durham, North Carolina, United States
Cincinnati Children's Hospital
Cincinnati, Ohio, United States
Oregon Health Science University School of Medicine
Portland, Oregon, United States
Monroe Carell Jr. Childrens Hospital at Vanderbilt
Nashville, Tennessee, United States
Childrens Medical Center of Dallas University of Texas Southwestern
Dallas, Texas, United States
Texas Children's Hospital
Houston, Texas, United States
Texas Liver Institute
San Antonio, Texas, United States
Cliniques Universitaires Saint-Luc Bruxelles
Brussels, , Belgium
Hôpital Femme Mère Enfant de Lyon
Bron, , France
Antenne pediatrique du CIC-Hopital Jeanne De Flandre
Lille, , France
Hopital Necker Enfants Malades
Paris, , France
Charité - Universitätsmedizin Berlin
Berlin, , Germany
Medizinische Hochschul
Hanover, , Germany
Universitatsklinik fur Kinder-und Jugendmedizin Tubingen
Tübingen, , Germany
AOU Meyer
Florence, , Italy
Azienda Ospedale University
Padua, , Italy
Ospedale Pediatrico Bambino Gesu
Rome, , Italy
University of Malaya Medical Center
Kuala Lumpur, , Malaysia
Universitair Medisch Centrum Groningen
Groningen, , Netherlands
Wilhelmina Children's Hospital UMCU Utrecht
Utrecht, , Netherlands
Instytut Pomnik-Centrum Zdrowia Dzieck
Warsaw, , Poland
Istanbul University Istanbul Medical Faculty Hospital
Istanbul, , Turkey (Türkiye)
Birmingham Women's and Children's NHS Foundation Trust
Birmingham, , United Kingdom
King's College Hospital NHS Foundation Trust King's College Hospital Paediatric Research
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Trung Van
Role: primary
Ashley Thomas
Role: backup
Heather Wasserkbury
Role: primary
Rozanne Groen
Role: primary
Yee Siong Chaw
Role: primary
Michelle Tran
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-509028-17-00
Identifier Type: CTIS
Identifier Source: secondary_id
2021-000996-36
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
A4250-015
Identifier Type: -
Identifier Source: org_study_id